"A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCeptTM, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability"

Administered By

Awarded By

Contributors

Start/End

  • January 2, 2019 - October 31, 2022